Background and Objective. CD27, a transmembrane homodimer belonging to the nerve growth factor (NGF) receptor superfamily, is typically expressed on leukemic CD5+ cells in B-cell chronic lymphocytic leukemia (CLL) and found in soluble form in the serum of CLL patients. Therefore, we investigated clinicobiological implications of increased serum levels of sCD27 in an unselected series of B-CLL patients. Design and Methods. Serum CD27 (sCD27) levels were determined at the time of diagnosis in 82 previously untreated B- CLL patients using a sandwich enzyme-linked immunoassay (ELISA). Results were correlated with either clinico-hematological or biological features. Finally, quantitative flow cytometric analyses of membrane CD27 (mCD27) expression were carried out on peripheral blood (PB) cells of 22 B-CLL patients and 5 healthy controls, respectively. Results. CD27 was found to be expressed on the surface of both resting normal and leukemic B cells. sCD27 levels were significantly higher in B-CLL patients (median value 2150 U/ml) than in healthy controls (median value 220 U/mL)(p<0.0001). There was a close relationship between sCD27 and soluble TNF-α, another molecule belonging to the NGF receptor superfamily. Changes in sCD27 level correlated with clinical stage, β2 microglobulin and LDH. Interpretation and Conclusions. These findings indicate the sCD27 is a reliable marker of tumor mass in B-CLL. Its potential prognostic value should be tested in prospective studies.
|Number of pages||5|
|Publication status||Published - May 1998|
- Chronic lymphocytic leukemia
ASJC Scopus subject areas